(Reuters) – AstraZeneca Plc said on Thursday its asthma treatment for a chronic inflammatory disease of the nasal passage linings, or sinuses, met main goals in a late-stage study.
The treatment, Fasenra, showed a statistically significant improvement in treating patients with severe bilateral nasal polyposis that were still symptomatic despite continued treatment with standard of care.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Anil D’Silva)
